The page announces a presentation on glioblastoma data, drug repurposing, and exosomal biomarkers at the ESN-ISN School and Hellenic Crystallographic Association Conference.
The page features an article in InScience about drug repurposing for rare diseases, highlighting the role of big data and AI in predicting drug efficacy and toxicity.
The company hosted a webinar titled *Innovative Approaches in Drug Repurposing: The CloudScreen Platform*, presenting its unified drug retargeting platform.
The National Foundation for Research (EIE), one of Greece’s largest research centers, was founded in 1958 under the supervision of the General Secretariat for Research and Technology (GGET) in the Ministry of Development and Investments.
CloudScreen integrates 1D and 3D data to identify drug-targetable proteomes and protein mutations/morphisms. It combines artificial and human intelligence to assess the efficacy and toxicity of repurposed and retargeted drugs.